Coronavirus vaccine could be ready sooner than expected: Health group
A vaccine to halt the coronavirus pandemic could be available as early as this year for vulnerable groups such as health-care workers, even faster than initially thought, according to a key group at the heart of the global development effort.
The Coalition for Epidemic Preparedness Innovations, which is funding nine different coronavirus vaccine projects, has previously suggested a shot could be ready within 12 to 18 months, an already ambitious target. That assessment didn’t account for the possibility of companies working closely together to accelerate the process, faster enrollment in human trials and other factors, according to Richard Hatchett, the head of the Oslo-based organization.
“These are all things we are looking at now as potential opportunities to perhaps deliver vaccines even faster than the 12 to 18 months we were discussing," he said on a call Monday.
As the number of coronavirus infections globally nears 3 million, the pressure is growing to come up with therapies and vaccines to combat the contagion. Dozens of companies around the world are pursuing a vaccine, among them Sanofi, Johnson & Johnson and Moderna Inc.
A University of Oxford team led by Sarah Gilbert, a professor of vaccinology, has begun trials of a potential vaccine and aims to get efficacy results as soon as September. Manufacturing is already underway.
Some experts have called for caution, noting that most vaccines go through years of tests before they hit the market, and that 12 to 18 months would be extraordinarily fast. The coronavirus shots moving most rapidly are made with new technologies that have never proven useful in humans.
Hatchett said he doesn’t want to overpromise, but several vaccines backed by CEPI may enter a second phase of testing as soon as late spring or this summer. That means the first could become available in 2020 if they prove to be safe and effective, probably on an emergency-use basis. In that scenario, they might be accessible only to certain at-risk populations before being deployed more widely.
Developers are mindful of examples in the past where rapid vaccine development “unfortunately led to bad outcomes," he said. “We take it with the utmost seriousness. We cannot cut corners. It’s absolutely critical that we ensure safety and efficacy."
With experimental vaccines progressing, governments and health groups are turning to the challenge of producing enough doses to meet global demand and ensuring that shots are distributed equitably. The coalition wants to set up manufacturing in every region of the world and has been talking with other groups including Gavi, the Vaccine Alliance, which helps developing countries finance and distribute vaccines.
“Given the economic disruption that is caused by the pandemic and the global interconnectedness of the economy, if we don’t address the pandemic everywhere, we will still be at risk," Hatchett said.
The head of Sanofi, Paul Hudson, raised questions last week about Europe’s ability to manufacture enough doses and said the U.S. may be in a position to vaccinate first, thanks to the Biomedical Advanced Research and Development Authority, a government agency that backs vaccine development.
“We should really have a global perspective and make sure we don’t end up limiting the access because it’s produced in certain countries," Erna Solberg, Norway’s prime minister, said on the call with CEPI’s head.
CEPI has secured commitments for about half of the $2 billion it estimates will be needed to develop the vaccines, and it may invest in 15 or more programs, Hatchett said.
A standard editorial manager system is utilized for manuscript submission, review, editorial processing and tracking which can be securely accessed by the authors, reviewers and editors for monitoring and tracking the article processing. Manuscripts can be uploaded online at Editorial Tracking System (https://www.scholarscentral.org/submissions/pharmaceutical-sciences-drug-development.html) or forwarded to the Editorial Office at: email@example.com
How we work:
- After submission, an acknowledgement with manuscript number is sent to the corresponding author within 7 working days.
- A 21 day window time frame is allotted for peer-review process wherein multiple experts are contacted.
- Author proof is generated within 7 working days after the acceptance decision.
Benefits on Publication:
Open Access: Permanent free access to your article upon publication ensures extensive global reach and readership.
Easy Article Sharing: Our open access enables you to share your article directly with colleagues through email and on social media via a single link, permitting third party reuse with appropriate citation in addition to the retention of content copyright by the author.
Global Marketing: Through promotion in a targeted global email announcement or press release, your article will be seen by thousands of the top-most thought-leaders in your field.
Color Art: In a world of black & white journal articles, high-quality full-color images make your article stand out from the crowd and tell a complete story, increasing readers and citations.
Social Media Exposure: Extended reach for your article through links on Twitter accounts provides maximum visibility worldwide.
Reprints: Distribute your work to colleagues and at conferences as we provide hard copy color reprints of your article on order.
Sarah Eve | Journal Manager
Journal of Pharmaceutical Sciences and Drug Development
Whatsapp No: +1-504-608-2390